Stoke Therapeutics (NASDAQ:STOK) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a report released on Tuesday morning,Benzinga reports.

A number of other research firms have also recently commented on STOK. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Price Performance

STOK opened at $13.26 on Tuesday. The firm has a fifty day moving average price of $12.44 and a 200 day moving average price of $13.69. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58. The stock has a market cap of $702.38 million, a P/E ratio of -6.31 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Equities analysts expect that Stoke Therapeutics will post -2.03 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 6,170 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the sale, the chief executive officer now directly owns 68,671 shares in the company, valued at $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Barry Ticho sold 13,945 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the completion of the sale, the insider now directly owns 47,332 shares of the company’s stock, valued at approximately $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,977,311 shares of company stock valued at $27,723,560. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after acquiring an additional 47,239 shares during the period. Geode Capital Management LLC raised its stake in Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after purchasing an additional 76,661 shares during the period. Jane Street Group LLC boosted its holdings in Stoke Therapeutics by 338.2% in the 3rd quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after purchasing an additional 255,028 shares during the last quarter. State Street Corp grew its stake in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares during the period. Finally, RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after buying an additional 427,447 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.